Cathay International Holdings Ld Result of Lansen EGM (0774E)

TIDMCTI

RNS Number : 0774E

Cathay International Holdings Ld

13 July 2016

Cathay International Holdings Limited

("Cathay" or the "Company")

Poll Results of Lansen Pharmaceutical Holdings Limited Extraordinary General Meeting ("EGM") Held on 13 July 2016

Hong Kong, 13 July 2016 - Cathay International Holdings Ltd. (LSE: CTI.L), a leading operator and investor in the growing healthcare sector in the People's Republic of China, today announces that its subsidiary Lansen Pharmaceutical Holdings Ltd ("Lansen") (HKEX: 503), in which the Company has a 50.56% holding, has announced that at its EGM held today, the proposed resolutions relating to the second tranche subscription in Haotian and the Cross Guarantee Agreement were duly passed by its independent shareholders.

The full text of the Lansen Announcement can be found at http://www.hkexnews.hk/listedco/listconews/SEHK/2016/0713/LTN20160713472.pdf and will also be made available at the Announcements & Notices section of Lansen's homepage at http://www.lansen.com.cn/En/Announcements&Notices.asp.

- ENDS -

For further enquiries, please contact:

 
 Cathay International Holdings 
  Limited                               Tel: [phone] 
  Eric Siu (Finance Director) 
  Patrick Sung (Director and 
  Controller) 
 Consilium Strategic Communications 
  Mary-Jane Elliott / Matthew           Tel: +44 (0) 203 
  Neal / Lindsey Neville                709 5702 
 

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC").

The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment.

For more information please visit the Company's website: www.cathay-intl.com.hk

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCKMGMNLFLGVZG

(END) Dow Jones Newswires

July 13, 2016 06:02 ET (10:02 GMT)